β-Lactamases identified in clinical isolates of Pseudomonas aeruginosa

Abstract

The increased prevalence of β-lactamases in Pseudomonas aeruginosa has begun to reduce the clinical efficacy of β-lactams against the most common opportunistic pathogen. Of over 800 β-lactamases identified from Gram-negative bacilli, at least 120 β-lactamases have been detected in P. aeruginosa. IMPs and VIMs are predominantly found in P. aeruginosa and like Acinetobacter spp., P. aeruginosa is also a predominant source of OXAs, indicating that P. aeruginosa is a crucial reservoir of β-lactam resistance determinants. This review summarizes the β-lactamases identified in clinical isolates of P. aeruginosa, with a particular focus on AmpC-type β-lactamases, extended-spectrum β-lactamases, and carbapenemases.

Keywords::

• Pseudomonas aeruginosa
• β-lactamases
• nosocomial infection